Caribou Biosciences (CRBU) Interest Expenses (2020 - 2021)
Caribou Biosciences (CRBU) reported Interest Expenses of $2000.0 for Q2 2021, down 60.0% year-over-year from $5000.0 in Q2 2020, and down 66.67% on a QoQ basis from $6000.0 in Q4 2020.
Caribou Biosciences (CRBU) has 2 years of Interest Expenses data on file, last reported at $2000.0 in Q2 2021.
- Quarterly Interest Expenses fell 60.0% year-over-year to $2000.0 in Q2 2021, while the trailing twelve-month figure through Mar 2022 was $2000.0 (down 88.24% YoY) and the FY2021 annual result came in at $8000.0, down 60.0% from the prior year.
- Interest Expenses eased to $2000.0 in Q2 2021 per CRBU's latest filing, from $6000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $6000.0 in Q3 2020 and bottomed at $2000.0 in Q2 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 2,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Dec 31, 2020 | 6,000.00 |
| Dec 31, 2020 | 6,000.00 |
| Sep 30, 2020 | 6,000.00 |
| Sep 30, 2020 | 6,000.00 |
| Jun 30, 2020 | 5,000.00 |
| Jun 30, 2020 | 5,000.00 |